Details of a Researcher

写真b

OJI Yuusuke

Keyword	the Wilms' tumor gene, WT1,cancer biology, cancer immunology
Mail Address
URL	http://sahswww.med.osaka-u.ac.jp/~hmtonc/index.html

1997.04.01 - 2003.03.31, Faculty of Medicine, Research Assistant
2003.04.01 - 2004.03.31, Division of Health Sciences, Graduate School of Medicine, Research Assistant
2004.04.01 - 2007.03.31, Division of Health Sciences, Graduate School of Medicine, Associate Professor
2007.04.01 - 2009.03.31, Division of Health Sciences, Graduate School of Medicine, Associate Professor
2009.04.01 - 2010.09.30, Graduate School of Medicine, Professor
2010.10.01 - 2017.03.31, Division of Health Sciences, Graduate School of Medicine, Professor
2017.04.01 - , Division of Health Sciences, Graduate School of Medicine, Professor

Osaka University Faculty of Medicine Graduated	M.D.	1990.03
Osaka University Faculty of Medicine Graduated		1994.06

Osaka University Graduate School of Medicine Associate Professor

2004.04 -

Immune adjuvant therapy using Bacillus Calmette-Guérin cell wall skeleton (BCG-CWS) in advanced malignancies: A phase 1 study of safety and immunogenicity assessments.. , Nishida S, Tsuboi A, Tanemura A, Ito T, Nakajima H, Shirakata T, Morimoto S, Fujiki F, Hosen N, Oji Y, Kumanogoh A, Kawase I, Oka Y, Azuma I, Morita S, Sugiyama H., Medicine (Baltimore)， 2019 Aug;98(33):e16771. 1., 2019.08, Papers
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia., Nakata J, Oji Y, Oka Y, Sugiyama H., Expert Rev Hematol，12: 211-213, 2019, 2019.04, Papers
What should we tackle next in acute myeloid leukemia? Wilms tumor gene 1 vaccine therapy would be a promising and versatile strategy for acute myeloid leukemia, Nakata J, Oji Y, Oka Y, Sugiyama H, Expert Review of Hematology，12(4) 211-213, 2019.04, Papers
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma, Tsuboi A. , et al., Cancer Immunology, Immunotherapy，68(2) 331-340, 2019.02, Papers
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. , Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, Sakamoto J, Oji Y, Oka Y, Sugiyama H. , Cancer Immunol Immunother., 2018.11, Papers